MK-5108 (VX-689)
(Synonyms: VX-689) 目录号 : GC17162
A potent inhibitor of Aurora kinases
Cas No.:1010085-13-8
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
MK-5108, also known as VX-689, is a novel, potent and selective inhibitor of Aurora A kinase (AAK) that competitively binds to the ATP binding site of AAK and hence potently inhibits the activity of AAK with 50% inhibition concentration IC50 value of 0.064 nM. MK-5108 also inhibits other members of Aurora kinase family, including Aurora B kinase (IC50 = 14 nM) and Aurora C kinase (IC50 = 12 nM), with a lesser potency. MK-5108 has been extensively studies and found to exhibit antitumor activity in a wide range of cancer types, including breast, cervix, colorectal, ovary and pancreas neoplasms.
Reference
[1].Myke R. Green, BS, Pharm.D., BCOP, Joseph E. Woolery, BS, Pharm.D, and Daruka Mahadevan, MD, PhD. Update on Aurora Kinase Targeted Therapeutics in Oncology. Recent Pat Anticancer Drug Discov. 2008 November ; 3(3): 162–177.
| Cell experiment: | |
|
Cell lines |
Tumor cell types (HCT116, LS174T, HL60, MDA-MB-231, ZR-75-1, MCF-7, PC3, MIA PaCa2, A375 and HeLa). |
|
Preparation method |
The solubility of this compound in DMSO is >10 mM. General tips for obtaining a higher concentration: Please warm the tube at 37 °C for 10 minutes and/or shake it in the ultrasonic bath for a while.Stock solution can be stored below -20°C for several months. |
|
Reaction Conditions |
48 h; IC50(15 nM-113 nM) |
|
Applications |
VX-680 caused accumulation of cells with 4 N DNA content and potently inhibited the proliferation of a wide variety of tumor cell types with half-maximal inhibitory concentration (IC50) values ranging from 15 to 113 nM. These data are consistent with the prediction that the Aurora kinases are crucial for cell-cycle progression, and with the finding that overexpression of kinase-inactive Aurora-B disrupts cell division. |
| Animal experiment: | |
|
Animal models |
Female athymic NCr-nu mice |
|
Dosage form |
75 mg/kg; b.i.d.i.p. |
|
Applications |
VX-680 caused a marked reduction in tumor size in a human AML (HL-60) xenograft model. In nude mice treated with VX-680 at 75 mg/kg, twice a day intraperitoneally (b.i.d.i.p.) for 13 d, mean tumor volumes were reduced by 98% (P < 0.001) in comparison with the control group. |
|
Other notes |
Please test the solubility of all compounds indoor, and the actual solubility may slightly differ with the theoretical value. This is caused by an experimental system error and it is normal. |
|
References: [1] Harrington E A, Bebbington D, Moore J, et al. VX-680, a potent and selective small-molecule inhibitor of the Aurora kinases, suppresses tumor growth in vivo[J]. Nature medicine, 2004, 10(3): 262-267. |
|
| Cas No. | 1010085-13-8 | SDF | |
| 别名 | VX-689 | ||
| 化学名 | 4-(3-chloro-2-fluorophenoxy)-1-[[6-(1,3-thiazol-2-ylamino)pyridin-2-yl]methyl]cyclohexane-1-carboxylic acid | ||
| Canonical SMILES | C1CC(CCC1OC2=C(C(=CC=C2)Cl)F)(CC3=NC(=CC=C3)NC4=NC=CS4)C(=O)O | ||
| 分子式 | C22H21ClFN3O3S | 分子量 | 461.94 |
| 溶解度 | ≥ 23.1 mg/mL in DMSO | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 2.1648 mL | 10.8239 mL | 21.6478 mL |
| 5 mM | 0.433 mL | 2.1648 mL | 4.3296 mL |
| 10 mM | 0.2165 mL | 1.0824 mL | 2.1648 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet